Holen Sie sich die Stockscreener-App
1.38
9.52%
0.12
Handel nachbörslich:
1.39
0.01
+0.72%
Schlusskurs vom Vortag:
$1.26
Offen:
$1.26
24-Stunden-Volumen:
833.95K
Relative Volume:
0.74
Marktkapitalisierung:
$112.30M
Einnahmen:
$139.77M
Nettoeinkommen (Verlust:
$-97.62M
KGV:
-0.8734
EPS:
-1.58
Netto-Cashflow:
$-61.71M
1W Leistung:
+5.34%
1M Leistung:
-0.72%
6M Leistung:
-58.18%
1J Leistung:
-66.34%
1-Tages-Spanne:
$1.26
$1.4065
1-Wochen-Bereich:
$1.185
$1.4065
52-Wochen-Spanne:
$0.9897
$5.77
Macrogenics Inc Stock (MGNX) Company Profile
Firmenname
Macrogenics Inc
Sektor
Branche
Telefon
301-251-5172
Adresse
9704 MEDICAL CENTER DRIVE, Rockville, MD
Vergleichen Sie MGNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.38 | 112.30M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-31 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-05-10 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-04-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-03-04 | Bestätigt | BTIG Research | Buy |
| 2024-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-22 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-11-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-02-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-04 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Hochstufung | Barclays | Underweight → Overweight |
| 2020-12-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2019-12-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Guggenheim | Neutral |
| 2019-02-07 | Hochstufung | Citigroup | Sell → Buy |
| 2019-02-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-02-06 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-12-10 | Herabstufung | Raymond James | Outperform → Underperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-05-31 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-31 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Macrogenics Inc Aktie (MGNX) Neueste Nachrichten
A Closer Look at Macrogenics Inc (MGNX) Stock Gains - investchronicle.com
MacroGenics (NASDAQ:MGNX) Shares Pass Below Two Hundred Day Moving Average – Time to Sell? - Defense World
MacroGenics’ SWOT analysis: biotech firm’s stock faces pivotal year ahead By Investing.com - Investing.com India
MacroGenics’ SWOT analysis: biotech firm’s stock faces pivotal year ahead - Investing.com
MacroGenics secures $70M from Sagard in royalty deal By Investing.com - Investing.com Nigeria
MacroGenics: Working On That Road To Recovery (NASDAQ:MGNX) - Seeking Alpha
MacroGenics lands $70M 'infusion of cash' to advance clinical programs - The Business Journals
MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Traders Buy High Volume of MacroGenics Call Options (NASDAQ:MGNX) - Defense World
MacroGenics (MGNX) Secures $70M Upfront Payment in Royalty Deal - GuruFocus
MacroGenics signs financial deal with Sagard for retifanlimab - Seeking Alpha
MacroGenics, Inc. and Sagard Healthcare Partners Enter into ZYNYZ Royalty Purchase Agreement - MarketScreener
MacroGenics, Sagard Sign Zynyz Royalty Purchase Deal - MarketScreener
MacroGenics at Goldman Sachs Conference: Strategic Pipeline Expansion - Investing.com Australia
United Natural Foods, Insmed, MacroGenics - TradingView
Transcript : MacroGenics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - marketscreener.com
MacroGenics at Goldman Sachs Conference: Strategic Pipeline Expansion By Investing.com - Investing.com Canada
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Roy - GuruFocus
MacroGenics, Inc. (NASDAQ:MGNX) Shares Bought by Bank of America Corp DE - Defense World
MacroGenics secures $70M from Sagard in royalty deal - Investing.com Australia
MacroGenics, Sagard Healthcare enter into ZYNYZ royalty purchase - TipRanks
MacroGenics stock soars on royalty deal with Sagard By Investing.com - Investing.com Nigeria
MacroGenics stock soars on royalty deal with Sagard - Investing.com Australia
MacroGenics Enters Royalty Purchase Agreement with Sagard - TipRanks
MacroGenics (MGNX) Secures $70 Million Through Royalty Agreement | MGNX Stock News - GuruFocus
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement - GlobeNewswire
Would I Choose Macrogenics Inc (NASDAQ: MGNX) Stock At Any Point In Time? - Stocksregister
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics LawsuitMGNX - ACCESS Newswire
MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug TrialHagens Berman - ACCESS Newswire
MacroGenics (NASDAQ:MGNX) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Ameriprise Financial Inc. Sells 26,544 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Brokerages Set MacroGenics, Inc. (NASDAQ:MGNX) PT at $5.71 - Defense World
HAGENS BERMAN, SHAREHOLDER ADVOCATES, Encourages MacroGenics (MGNX) Investors With Significant Losses to Contact Its Attorneys, 6-Day Application Deadline is Approaching - ACCESS Newswire
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages MacroGenics (MGNX) Investors With Significant Losses to Contact Its Attorneys, 5-Day Application Deadline is Approaching in Securities Class Action - ACCESS Newswire
MacroGenics to Present at the Goldman Sachs 46th Annual Global H - GuruFocus
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | MGNX Stock News - GuruFocus
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - GlobeNewswire
MacroGenics Executives Set for Major Goldman Sachs Healthcare Conference Presentation: Watch Live - Stock Titan
Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 – MGNX - ACCESS Newswire
MacroGenics (NASDAQ:MGNX) Upgraded to Hold at Wall Street Zen - Defense World
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc.(MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
MacroGenics’ SWOT analysis: biotech firm’s stock faces pipeline challenges By Investing.com - Investing.com South Africa
MacroGenics’ SWOT analysis: biotech firm’s stock faces pipeline challenges - Investing.com
Lazard Asset Management LLC Purchases New Position in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Northern Trust Corp Has $1.76 Million Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Millennium Management LLC Sells 671,179 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Q2 Earnings Forecast for MacroGenics Issued By B. Riley - Defense World
MacroGenics Holds Annual Stockholders Meeting on May 21 - TipRanks
B. Riley Issues Pessimistic Forecast for MacroGenics (NASDAQ:MGNX) Stock Price - Defense World
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies - Yahoo Finance
Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher - simplywall.st
Finanzdaten der Macrogenics Inc-Aktie (MGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Macrogenics Inc-Aktie (MGNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Karrels James | SVP, CFO and Secretary |
Feb 15 '25 |
Option Exercise |
0.00 |
14,998 |
0 |
192,591 |
| Koenig Scott | President and CEO |
Feb 15 '25 |
Option Exercise |
0.00 |
42,329 |
0 |
777,415 |
| Peters Jeffrey Stuart | Senior VP and General Counsel |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
18,858 |
| Risser Eric Blasius | Chief Operating Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
62,422 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Option Exercise |
0.00 |
1,095 |
0 |
9,955 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Sale |
2.56 |
423 |
1,083 |
9,532 |
| Spitznagel Thomas | Sr VP, Technical Ops |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
26,922 |
| Eck Stephen L. | Chief Medical Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
34,319 |
| Eck Stephen L. | Chief Medical Officer |
Feb 08 '25 |
Option Exercise |
0.00 |
11,168 |
0 |
20,966 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):